A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus
A Double-blind, Placebo-controlled, Multiple-Dose, 2-Period Crossover Study to Evaluate the Effect of Steady-state AZD6793 on the Steady-state Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus
AstraZeneca
28 participants
Jan 14, 2026
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to examine the effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus.
Eligibility
Inclusion Criteria5
- Physician-diagnosis of T2DM
- On a stable dose of metformin 2000 mg per day for at least 3 months prior to screening.
- stable glycaemic control indicated by no change in treatment for diabetes within 3 months prior to screening
- HbA1c (Hemoglobin A1c) ≤ 8.5% at screening
- Body Mass Index (BMI) within the range 18.5 to 35 kg/m2 , inclusive, at screening.
Exclusion Criteria5
- Physician diagnosis of type 1 diabetes.
- History of any clinically important disease or disorder.
- History or presence of chronic Gastrointestinal, hepatic, renal, or pancreatic disease
- History of Human immunodeficiency viruses (HIV) infection or a positive HIV test.
- History of prior episode(s) of lactic acidosis.
Interventions
Participants will receive oral doses of metformin with an interval of 12 hours between doses. The morning doses of metformin will be administered together with AZD6793 (Treatment A).
Participants will receive oral doses of metformin with an interval of 12 hours between doses. The morning doses of metformin will be administered together with AZD6793 placebo (Treatment B).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07433062